Connect
MJA
MJA

Australia reschedules naloxone for opioid overdose

Simon R Lenton, Paul M Dietze and Marianne Jauncey
Med J Aust 2016; 204 (4): 146-147. || doi: 10.5694/mja15.01181

The Therapeutic Goods Administration has changed naloxone scheduling to make it available over the counter

On 24 November 2015, the Therapeutic Goods Administration (TGA) announced its final decision to place “naloxone when used for the treatment of opioid overdose” on Schedule 3, thereby allowing over-the-counter (OTC) purchase.1 This measure came into effect on 1 February 2016, making Australia the second country, after Italy (in 1995), to have naloxone formally available OTC.

Please login with your free MJA account to view this article in full

  • Simon R Lenton1
  • Paul M Dietze2
  • Marianne Jauncey3

  • 1 National Drug Research Institute, Curtin University, Perth, WA
  • 2 Burnet Institute, Melbourne, VIC
  • 3 Sydney Medically Supervised Injecting Centre, Sydney, NSW

Correspondence: s.lenton@curtin.edu.au

Acknowledgements: 

The National Drug Research Institute receives funding from the Australian Government Department of Health. The Burnet Institute receives funding through the Victorian Governmentboyuan;rsquo;s Operational Infrastructure Support Program. Paul Dietze is a National Health and Medical Research Council Senior Research Fellow. Marianne Jauncey is employed by UnitingCare as Medical Director of the Sydney Medically Supervised Injecting Centre, which is funded by confiscated proceeds of illicit activity (funds that are managed by NSW Treasury). These funding bodies had no role in drafting or submitting this article.

Competing interests:

Simon Lenton receives funding from the Australian Government Department of Health through its core funding of the National Drug Research Institute and has conducted research-based advocacy for the wider availability of naloxone for more than 10 years. Paul Dietze has been the recipient of an untied educational grant from Reckitt Benckiser. Marianne Jauncey is the Medical Director of the Medically Supervised Injecting Centre and the naloxone prescriber for all onsite THN training at this centre.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.